[1]
Höckel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst., 2001, 93(4), 266-276.
[2]
Harris, A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2(1), 38-47.
[3]
Höckel, M.; Schlenger, K.; Höckel, S.; Vaupel, P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res., 1999, 59(18), 4525-4528.
[4]
Brahimi-Horn, M.C.; Pouysségur, J. Oxygen, a source of life and stress. FEBS Lett., 2007, 581(19), 3582-3591.
[5]
Lee, D.C.; Sohn, H.A.; Park, Z.Y.; Oh, S.; Kang, Y.K.; Lee, K.M.; Kang, M.; Jang, Y.J.; Yang, S.J.; Hong, Y.K.; Noh, H.; Kim, J.A.; Kim, D.J.; Bae, K.H.; Kim, D.M.; Chung, S.J.; Yoo, H.S.; Yu, D.Y.; Park, K.C.; Yeom, Y.I. A Lactate-induced response to hypoxia. Cell, 2015, 161(3), 595-609.
[6]
Melotte, V.; Qu, X.; Ongenaert, M.; Van, C.W.; Bruïne, A.P.; Baldwin, H.S.; Van, E.M. The N-myc downstream regulated gene (NDRG) family: Diverse functions, multiple applications. FASEB J., 2010, 24(11), 4153-4166.
[7]
Yang, X.; An, L.; Li, X. NDRG3 and NDRG4, two novel tumor-related genes. Biomed. Pharmacother., 2013, 67(7), 681-684.
[8]
Hwang, J.; Kim, Y.; Kang, H.B.; Jaroszewski, L.; Deacon, A.M.; Lee, H.; Choi, W.C.; Kim, K.J.; Kim, C.H.; Kang, B.S.; Lee, J.O.; Oh, T.K.; Kim, J.W.; Wilson, I.A.; Kim, M.H. Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor. JBC, 2011, 286(14), 12450-12460.
[9]
Wang, W.; Li, Y.; Li, Y.; Hong, A.; Wang, J.; Lin, B.; Li, R. NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. IJC, 2009, 124(3), 521-530.
[10]
Ren, G.F.; Tang, L.; Yang, A.Q.; Jiang, W.W.; Huang, Y.M. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy. Histol. Histopathol., 2014, 29(4), 535-542.
[11]
Fan, C.G.; Wang, C.M.; Tian, C.; Wang, Y.; Li, L.; Sun, W.S.; Li, R.F.; Liu, Y.G. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol. Rep., 2011, 26(5), 1281-1286.
[12]
Zhao, W.; Tang, R.; Huang, Y.; Wang, W.; Zhou, Z.; Gu, S.; Dai, J.; Ying, K.; Xie, Y.; Mao, Y. Cloning and expression pattern of the human NDRG3 gene. BBA-Mol. Cell Biol. L., 2001, 1519(1-2), 134-138.
[13]
Martí-Renom, M.A.; Stuart, A.C.; Fiser, A.; Sánchez, R.; Melo, F.; Šali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Bioph. Biom., 2000, 29(1), 291-325.
[14]
Insight user guide; san Diego: Molecular Simulation Inc, 2000.
[15]
Kalia, M.; Singh, P.K.; Yadav, V.K.; Yadav, B.S.; Sharma, D.; Narvi, S.S.; Mani, A.; Agarwal, V. Structure based virtual screening for identification of potential quorum sensing inhibitors against LasR master regulator in Pseudomonas aeruginosa. Microb. Pathog., 2017, 107, 136-143.
[16]
Bowie, J.U.; Lüthy, R.; Eisenberg, D. A method to identify protein sequences that fold into a known three-dimensional structure. Science, 1991, 253(5016), 164-170.
[17]
Gandhi, S.; Puri, V.; Puri, S. Gankyrin: A potential target for drug therapy against hepatocellular carcinoma. JBiSE., 2012, 5(8), 469-475.
[18]
Cooper, M.J. Fluprostenol in mares: Clinical trials for the treatment of infertility. Vet. Rec., 1976, 98(26), 523-525.
[19]
Hu, S.; Huang, C.; Chen, B. Enhanced cytotoxity of VM-26 in human malignant glioma cells by calcium channel blocker nicardipine in vitro. Bullet Hunan Med. Uni., 1999, 24(2), 143-146.
[20]
Zhou, T.; Han, M.M.; Chen, S.L.; Zhao, Y.; Li, W.; Zhang, H.G.; He, T.H. Effect of cloprostenol sodium on the growth of human ovarian cancer cell lines in vitro. Prog. Veterinary Med., 2009, 30(10), 18-22.
[21]
Bertolesi, G.E.; Shi, C.; Elbaum, L.; Jollimore, C.; Rozenberg, G.; Barnes, S.; Kelly, M.E. The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol. Pharmacol., 2002, 62(2), 210-219.
